指南与共识前列腺癌

指南之指南:晚期前列腺癌中镥-177 PSMA放射配体治疗

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.
指南 / 共识 · BJU Int · 2026-04-14

除ESMO外,各学会均推荐177Lu-PSMA-617用于PSMA阳性mCRPC(既往ARPI和紫杉烷化疗后),部分指南基于PSMAfore试验谨慎扩展至紫杉烷未治人群;推荐方案为每6周7.4 GBq最多六周期,同步ADT和多学科管理。

要点

  • 177Lu-PSMA-617获推荐用于PSMA阳性mCRPC,既往需ARPI和紫杉烷化疗。
  • NCCN 2025和EAU 2025基于PSMAfore承认向紫杉烷未治人群扩展。
  • 推荐方案为每6周7.4 GBq最多六周期,同步ADT并多学科 oversight。

核心结论

  • 国际指南在PSMA-RLT的患者选择、剂量和多学科实施上总体趋同。
  • 正在进行的PSMAfore、PSMAddition、UpFrontPSMA、ENZA-p和LuTectomy试验将进一步明确其早期和联合治疗角色。

研究设计与样本

  • 纳入六部主要学会指南:EAU 2025、AUA/SUO 2023、NCCN 2025、CUA 2024、ASCO 2025、ESMO 2020,以及EANM/SNMMI 2023操作指南和APCCC 2024专家共识。

主要发现

  • 除ESMO尚未更新PSMA-RLT指南外,所有学会均认可177Lu-PSMA-617用于PSMA阳性mCRPC,依据VISION和TheraP试验的Level 1证据。
  • 基于PSMAfore,NCCN 2025版和更谨慎的EAU 2025指南承认向ARPI治疗后进展的紫杉烷未治患者扩展。

关键数值与推荐

  • 推荐方案:7.4 GBq每6周,最多六周期,同步雄激素剥夺治疗和多学科 oversight。
  • 177Lu-PSMA-617适用于PSMA阳性mCRPC,既往接受过ARPI和紫杉烷化疗。

临床怎么用

  • 临床可依据指南选择PSMA阳性mCRPC患者,在ARPI和紫杉烷化疗后使用177Lu-PSMA-617。
  • 实施时按每6周7.4 GBq最多六周期给药,同步ADT并多学科管理。
  • 对ARPI治疗后进展的紫杉烷未治患者,可参考NCCN 2025和EAU 2025的扩展推荐谨慎评估。

局限性

  • ESMO指南尚未更新PSMA-RLT推荐。
  • 早期和联合治疗设置的角色尚待PSMAfore、PSMAddition等试验进一步明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To synthesise current international guidance on lutetium-177-labelled prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy (RLT) across the prostate cancer disease spectrum, with emphasis on metastatic castration-resistant prostate cancer (mCRPC) and emerging earlier-line indications. METHODS: A structured literature overview was conducted. PubMed, EMBASE, and official repositories of major urological, oncological, and nuclear medicine societies were searched from inception to 31 October 2025 for prostate cancer guidelines. National and international guidelines or consensus statements published in English were eligible if they provided explicit recommendations regarding 177Lu-PSMA-RLT in their most recent version. Documents without therapeutic recommendations or superseded by updated versions were excluded. Six major society guidelines were included: European Association of Urology (EAU 2025), American Urological Association/Society of Urologic Oncology (AUA/SUO 2023), National Comprehensive Cancer Network (NCCN 2025), Canadian Urological Association (CUA 2024), American Society of Clinical Oncology (ASCO 2025), and European Society for Medical Oncology (ESMO 2020). The joint European Association of Nuclear Medicine/Society of Nuclear Medicine and Molecular Imaging (EANM/SNMMI 2023) procedural guideline and expert consensus from the Advanced Prostate Cancer Consensus Conference (APCCC 2024) were also reviewed. RESULTS: All societies except ESMO, which has not yet updated its guidance on PSMA-RLT, endorse 177Lu-PSMA-617 for PSMA-positive mCRPC following prior androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy, supported by Level 1 evidence from the VISION and TheraP trials. Following PSMAfore, NCCN version1.2025, and more cautiously the EAU 2025 guideline, acknowledge expansion into taxane-naïve patients progressing after ARPI therapy. The recommended regimen remains 7.4 GBq every 6 weeks for up to six cycles with concurrent androgen deprivation therapy and multidisciplinary oversight. CONCLUSIONS: International guidelines largely converge on patient selection, dosing, and multidisciplinary implementation of PSMA-RLT. Ongoing trials including PSMAfore, PSMAddition, UpFrontPSMA, ENZA-p, and LuTectomy are expected to further define its role in earlier and combination treatment settings.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Al-Khanaty A, Chen D, Walbaum J, et al. Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer. BJU Int. 2026. PMID: 41979224. doi:10.1111/bju.70283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。